{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Cumulative incidence of death without evidence of disease progression at 1 year","groups":[{"description":"Patients receive fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1. Patients undergo donor peripheral blood stem cell transplant on day 0. Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is \\>= 1,000/mm\\^3 for three consecutive days.","id":"OG000","title":"Treatment (Nonmyeloablative HCT, TBI)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Non-relapse Mortality at 1 Year","type":"PRIMARY","unitOfMeasure":"percent of participants"}